skip to Main Content

About AIONX®

What We Do

AIONX® is defining the emerging class of continuous, self-cleaning technologies.

Iocns-04

The AIONX® technology harnesses and enhances the natural cleaning capabilities of silver and copper to continuously clean treated surfaces. Our patented technology forces the rapid release of antimicrobial silver and copper ions by the novel use of a specially-designed micro electric circuit.*  Click HERE for more information about how the technology works.

Iocns-03

The AIONX® technology provides powerful, continuous cleaning efficacy through the active release of antimicrobial silver and copper ions.* Other continuous cleaners use passive and slower release mechanisms resulting in minimal efficacy, while surfaces cleaned with episodic (or non-continuous) cleaners begin to be re-contaminated immediately after the cleaning stops.

Icon_4

Third party researchers have performed numerous in vitro and clinical studies of the AIONX® technology to assess its ability to impact gram positive and gram negative bacteria, viruses, and antibiotic-resistant pathogens.* Click HERE for more information about Research+Results.

Management Team

Gary J. Shope

Chief Executive Officer

Most recently was CEO of Medafor, Inc., where led the company to a successful $200 million acquisition by C.R. Bard; Gary brings 35 years of executive, marketing and sales experience in the medical device arena with a focus on innovation, market-making, and building shareholder value.

Thomas Fuller

Chief Technology Officer

Thomas invented the AIONX® technology and now leads the company’s refinement and continued development of its technology and product offerings. Thomas has broad engineering and manufacturing experience, including a focus on designing medical devices. B.S. and M.S., Penn State University; MBA, Penn State University; 3.5 years toward M.D., Thomas Jefferson University Medical College.

Seth Zimmerman

Vice President, Business Development

Seth’s prior experience includes time as a corporate attorney and as a business advisor focused on assisting clients with raising capital and developing business strategies. He focuses on creating value with the AIONX® technology through a combination of sales and business relationships. B.A., Amherst College; J.D., Penn State; MBA, Carnegie Mellon University Tepper School of Business.

Board of Directors

James Hart, MD.

Dr. Hart retired in 2014 from Johnson & Johnson as its Chief Medical Officer and VP of Medical Affairs for its Global Surgery Group, having previously served as Chief Medical Officer for Ethicon. Prior to that, Dr. Hart had a distinguished 20-year career as a cardiovascular and thoracic surgeon.

Captain (Ret.) Ryan McCombie (Chairman)

Retired U.S. Navy Captain (SEAL), beginning with a SEAL tour in Vietnam and including training and serving with commandos from all over the world. He has consulted with and served as an advisor to and board member of both national and international companies.

Gautam Patel

Senior Advisor at LSH Partners and Managing Director of Tarsadia Investments, LLC, a private investment firm based in Newport Beach, California. Previously, an investment banker at Lazard, JPMorgan and Donaldson, Lufkin & Jenrette. University of Chicago, MBA; London School of Economics, MSc. Finance; Harvey Mudd College, B.S. Engineering; and Claremont McKenna College, B.S. Management-Engineering.

Gary Shope

Most recently was CEO of Medafor, Inc., where led the company to a successful $200 million acquisition by C.R. Bard; Gary brings 35 years of executive, marketing and sales experience in the medical device arena with a focus on innovation, market-making, and building shareholder value.

Jon Zimmerman

Retired CEO with 25 years’ experience in steel and aerospace industries, leading one company through a successful management buyout and significant recapitalization. Now serves on board of directors of multiple organizations, including a hospital and several government economic development committees.

* The AIONX® technology is registered with the EPA (EPA Reg. No. 91681-1) as an antimicrobial agent that effectively inhibits the growth of bacteria, fungi, algae, mold, and mildew that cause unpleasant odors, discoloration, staining, deterioration or corrosion on surfaces to which it is applied. The EPA has not reviewed or approved, nor does AIONX® make, any claims that its technology has efficacy against any particular pathogenic microbes. Use of the AIONX® technology at a use site is a supplement to surface cleaning and is not a substitute for standard infection control practices; users must continue to follow all current infection control practices, including those practices related to cleaning and disinfection of environmental surfaces.